TELA Bio, Inc., a commercial-stage medical technology company, has announced promising scientific research results for its OviTex Inguinal Reinforced Tissue Matrix. The product, specifically engineered for laparoscopic and robotic-assisted inguinal hernia repair, has been launched in the European market following its successful introduction in the U.S., where it achieved over $1 million in sales in its first year. A retrospective study led by Dr. Paul Szotek from the Indiana Hernia Center examined the OviTex Core Permanent using the Reinforced Biologic Augmented Repair (ReBAR) technique in 259 patients. The study demonstrated a low 1.2% recurrence rate with an average follow-up of 1.5 years, highlighting the product's clinical efficacy. OviTex Inguinal is available in Europe in two configurations, designed for compatibility with laparoscopic and robotic procedures, and offers a naturally derived alternative to synthetic mesh for hernia repair.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.